White blood cells (leukocytes), which are a subset of cytokines (secreted proteins and signaling molecules), were the first to be observed to express interleukins. Interleukins are crucial for the immune system's proper operation, and there have been rare cases of their deficiency that have all been associated with autoimmune disorders or immune deficiencies. Helper CD4 T lymphocytes, along with monocytes, macrophages, and endothelial cells, produce the majority of interleukins. They support the growth and differentiation of hematopoietic cells, including T and B lymphocytes. The development of spatial memories in mice has also been linked to interleukin receptors on astrocytes in the hippocampus.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V75030 | Dovanvetmab (ZTS-00521505) | 2171034-71-0 | Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. | |
V74927 | Dupilumab (Dupilumab; REGN-668; SAR-231893) | 1190264-60-8 | Dupilumab (REGN-668) is a fully human monoclonal antibody (mAb) directed against IL-4 receptor alpha (IL-4Rα) that can inhibit IL-4 and IL-13 signaling and significantly improves moderate to severe atopic dermatitis . | |
V74998 | Eblasakimab (ASLAN004; CSL-334) | 2445460-16-0 | Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells. | |
V74991 | Efineptakin alfa (NT-17) | 2026634-47-7 | Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. | |
V75000 | Efmarodocokin alfa | 2247840-74-8 | Efmarodocokin alfa is a fusion protein of human IL-22 and the crystallizable fragment of IgG4. | |
V74946 | Elsilimomab (B-E8; Anti-IL-6 MAB B-E8; Anti-Human IL6 Recombinant Antibody) | 468715-71-1 | Elsilimomab (B-E8) is an IgG1 monoclonal antibody (mAb) against interleukin-6 (IL-6) with a KD of 22 pM and IC50 of 1.4 nM. | |
V74885 | Elubricin tosylate (SB-656933 tosylate) | 960495-43-6 | Elubbrixin tosylate (SB-656933 tosylate) is a specific, competitive, reversible and orally bioactive CXCR2 antagonist and IL-8 receptor antagonist. | |
V75036 | Enokizumab (MEDI-528) | 909875-08-7 | Enokizumab (MEDI-528) is a monoclonal antibody (mAb) targeting interleukin IL-9. | |
V74967 | Fezakinumab (ILV 094) | 1007106-86-6 | Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody (mAb). | |
V74962 | Fletikumab (NNC 0109-0012) | 1357158-22-5 | Fletikumab (NNC0109-0012) is a monoclonal antibody (mAb) targeting IL-20. | |
V74940 | Gevokizumab | 1129435-60-4 | Gevokizumab is a potent anti-IL-1β antibody that negatively regulates IL-1β signaling through an allosteric mechanism. | |
V74990 | Goflikicept (RPH 104) | 2416984-26-2 | Goflikicept (RPH 104) is a hybrid protein that selectively binds and inactivates circulating IL-1ß and IL-1α. | |
V75005 | Gumokimab (AK 111) | 2428381-52-4 | Gumokimab (AK 111) is a monoclonal antibody (mAb) targeting IL-17A and may be utilized in the research of psoriasis and ankylosing spondylitis. | |
V75013 | Hedycoronen A | 1383441-73-3 | Hedycoronen A exhibits inhibitory effect on the production of IL-6, IL-12 p40 and TNF-α in LPS-stimulated BMDC, with IC50s of 9.1 μM, 5.6 μM and 46.0 μM, respectively. | |
V75032 | IL-17 modulator 1 | 2446803-85-4 | IL-17 modulator 1 is an orally bioactive, highly efficient small molecule IL-17 modulator, found in patent WO 2020127685. | |
V74965 | IL-17 modulator 1 disodium | 2446803-91-2 | IL-17 modulator 1 (disodium) is an orally bioactive, highly efficient small molecule IL-17 modulator, found in patent WO 2020127685. | |
V75010 | IL-17 modulator 2 | 1449208-36-9 | IL-17 modulator 2 (compound 159) is an orally bioactive modulator of IL-17. | |
V74961 | IL-17 modulator 3 | 2467731-88-8 | IL-17 modulator 3 is an IL-17 modulator (US20200247785A1). | |
V74982 | IL-17 modulator 4 sulfate | 2446806-90-0 | IL-17 modulator 4 sulfate is a precursor to IL-17 modulator 1. | |
V75024 | IL-17 modulator 5 | 2724206-27-1 | IL-17 modulator 5 (compound 26) is an inhibitor (blocker/antagonist) of IL-17 with IC50 of 1 nM. |